SEQENS and Rondol Group are pleased to announce their collaboration in formulation research and continuous flow manufacturing for existing, repurposed or new drugs in the form of extruded oral doses. Our partnership is based on the complementarity expertises of Seqens as a global leader in designing, developing and manufacturing small molecules Active Pharmaceutical Ingredients and Rondol for the development and continuous improvement of drug dosage extrusion technologies. The goal is to launch faster new biotech inventions as well as to redesign, lower cost and reduce potential side effects of some traditional treatments – in particular for drugs with potential toxicity concerns and for which the required dosage for treatment is estimated to be high. And also to enable a better and faster response to future pandemics. Pierre Luzeau states: « We count on this collaboration to bring value to our customers and further increase our portfolio of cutting-edge technologies and services we master in our 7 R&D centers around the world.” And we at RONDOL see this partnership as a major step to offer our common customers a strong technology expertise in order to bring sound and fast to the market new or repurposed drugs at competitive costs.